Keros Therapeutics KROS
NASDAQ KROS
$11.23 -0.17 (-1.49%)
As of: Oct 21, 2026 · 2:51 PM EDT

Keros Therapeutics (KROS) EV to EBIT (2025)

Updated

Keros Therapeutics' (KROS) EV to EBIT came in at 6.96 for Q4 2025.

Analysis

Keros Therapeutics (KROS) EV to EBIT (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.71 Bn 1,105.29 Bn 19.71 Bn
2 Johnson & Johnson 617.55 Bn 536.07 Bn 17.26 Bn
3 AbbVie 501.02 Bn 474.13 Bn 12.70 Bn
4 Merck 368.18 Bn 322.56 Bn 12.21 Bn
5 Novartis Ag 297.89 Bn 261.88 Bn 11.24 Bn
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn
7 Amgen 236.60 Bn 191.99 Bn 7.24 Bn
8 Gilead Sciences 190.55 Bn 164.75 Bn 6.22 Bn
9 Pfizer 169.77 Bn 116.42 Bn 10.94 Bn
10 Keros Therapeutics 222.56 Mn -1.71 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 6.96
Sep 30, 2025 -1.16
Jun 30, 2025 -474.36
API Access

Keros Therapeutics EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=KROS&period=max&api_key=YOUR_API_KEY